SomaLogic (CM Life Sciences II) ^{Priced, Nasdaq: SLGC}

We are a newly organized blank check company. While we may pursue an initial business combination target in any industry, sector or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. Our team intends to leverage the strong life sciences knowledge base and public and private market experience of our sponsor with the goal of executing a successful business combination in the life sciences sector. Our sponsor is an affiliate of Eli Casdin, founder and Chief Investment Officer of Casdin Capital, and of Keith Meister, founder and Chief Investment Officer of Corvex Management, two leading investment firms. CM Life Sciences II has a focused acquisition strategy. We believe that the rise in both the number and quality of companies entering the genomics space today presages significant consolidation and restructuring. Our comprehensive understanding of the science, strong ties to the industry, and broad experience guiding public companies gives us a competitive advantage to help shape, and profit from, this key moment in the maturation of the industry.